Earnings

Immix Reports $13.9 Million Third-Quarter 2026 Net Loss, 89% Complete Response Rate in NEXICART-2

The Tip Desk · November 13, 2026 · 2 min read

The amyloidosis CAR-T developer posted $15.9 million in third-quarter 2026 operating expenses and a $13.9 million net loss as it readied a mid-2027 BLA.

Immix Biopharma, Inc. (IMMX) reported operating expenses of $15.9 million and a net loss of $13.9 million for the third quarter ended September 30, 2026. The company, a global leader in AL amyloidosis, reported an 89% complete response rate across all 45 patients in its NEXICART-2 trial of NXC-201, its sterically optimized BCMA-targeted CAR-T cell therapy, and said minimal residual disease negativity indicated potential to reach up to a 98% complete response rate in the future.

The company said it continues to advance AL amyloidosis launch readiness across commercial site activation, provider and payer engagement, manufacturing, and healthcare professional education. Interim NEXICART-2 results were selected for an oral presentation at the 68th American Society of Hematology annual meeting on December 14, 2026, in New Orleans.

Immix plans a BLA submission in mid-2027 and initiation of the NEXICART-3 front-line trial in the first half of 2027. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL amyloidosis with a potentially registrational design and has been awarded Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy by the FDA, and Orphan Drug Designation by the FDA and the EMA.

Cash, cash equivalents and marketable securities were $340.9 million as of September 30, 2026, up from $234.1 million as of June 30, 2026. The company said the balance is expected to provide operating runway into mid-2028.

For the three months ended September 30, 2026, operating expenses were $15.9 million, comprising $5.5 million of research and development costs and $10.4 million of general and administrative costs, producing an operating loss of $15.9 million. Net loss for the quarter was $13.9 million after $2.0 million of interest income.

Financing activities provided $119.2 million of cash in the three months ended September 30, 2026. Operating activities used $12.3 million and investing activities used $12.0 million.

Immix appointed David He, MD, PhD, as Senior Vice President, Head of Technical Operations, to lead chemistry, manufacturing, and controls. Dr. He has contributed in a senior role to two approved BCMA CAR-Ts, CARVYKTI and FUCASO. The company said the hire is intended to further accelerate its planned path to commercialization. It also appointed Karin McIntosh as Senior Vice President, Head of Regulatory Affairs, and added other members across Commercial, Regulatory, Quality, Medical Affairs, and Medical Science Liaison roles.

The company said the number of patients in the U.S. with relapsed/refractory AL amyloidosis is estimated to be growing at 12% per year to approximately 30,506 patients in 2026, and that the amyloidosis market was $6.2 billion in 2025 and is expected to reach $6.6 billion in 2026.

Immix also said it will present at the 45th Annual J.P. Morgan Healthcare Conference in San Francisco from January 11 to 14, 2027.